Comparative Pharmacology
Head-to-head clinical analysis: CORDRAN N versus DIFICID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORDRAN N versus DIFICID.
CORDRAN N vs DIFICID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cordran N contains flurandrenolide, a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions by inducing phospholipase A2 inhibitory proteins (lipocortins) and modulating gene expression; neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, leading to RNA synthesis inhibition and cell death. It is bactericidal against Clostridioides difficile and has minimal systemic absorption.
Apply sparingly to affected area 2-3 times daily. Use for no longer than 2 weeks.
200 mg (tablet) orally twice daily for 10 days.
None Documented
None Documented
Approximately 1-2 hours. Short half-life consistent with topical use; systemic exposure minimal with proper application.
11.7 hours (terminal half-life in healthy subjects); supports twice-daily dosing.
Primarily renal (biliary/fecal minimal). Unchanged drug and glucuronide metabolites excreted in urine.
Fecal (primarily as unchanged drug, ~44% of dose); renal (~1.6% unchanged, <1% as metabolites); biliary (minor).
Category C
Category C
Topical Corticosteroid + Antibiotic
Antibiotic